APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition

  1. Sandra R Richardson
  2. Iñigo Narvaiza
  3. Randy A Planegger
  4. Matthew D Weitzman
  5. John V Moran  Is a corresponding author
  1. University of Michigan Medical School, United States
  2. The Salk Institute for Biological Studies, United States
  3. University of Pennsylvania Perelman School of Medicine and the Children's Hospital of Philadelphia, United States

Abstract

Long INterspersed Element-1 (LINE-1 or L1) retrotransposition poses a mutagenic threat to human genomes. Human cells have therefore evolved strategies to regulate L1 retrotransposition. The APOBEC3 (A3) gene family consists of seven enzymes that catalyze deamination of cytidine nucleotides to uridine nucleotides (C-to-U) in single-strand DNA substrates. Among these enzymes, APOBEC3A (A3A) is the most potent inhibitor of L1 retrotransposition in cultured cell assays. However, previous characterization of L1 retrotransposition events generated in the presence of A3A did not yield evidence of deamination. Thus, the molecular mechanism by which A3A inhibits L1 retrotransposition has remained enigmatic. Here, we have used in vitro and in vivo assays to demonstrate that A3A can inhibit L1 retrotransposition by deaminating transiently exposed single-strand DNA that arises during the process of L1 integration. These data provide a mechanistic explanation of how the A3A cytidine deaminase protein can inhibit L1 retrotransposition.

Article and author information

Author details

  1. Sandra R Richardson

    University of Michigan Medical School, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  2. Iñigo Narvaiza

    The Salk Institute for Biological Studies, La Jolla, United States
    Competing interests
    No competing interests declared.
  3. Randy A Planegger

    University of Michigan Medical School, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  4. Matthew D Weitzman

    University of Pennsylvania Perelman School of Medicine and the Children's Hospital of Philadelphia, Philadelphia, United States
    Competing interests
    No competing interests declared.
  5. John V Moran

    University of Michigan Medical School, Ann Arbor, United States
    For correspondence
    moranj@umich.edu
    Competing interests
    John V Moran, is an inventor on patent 6,150,160. Kazazian HH, Boeke JD, Moran JV, Dombroski BA: Compositions and methods of use of mammalian retrotransposons.

Copyright

© 2014, Richardson et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,912
    views
  • 261
    downloads
  • 115
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sandra R Richardson
  2. Iñigo Narvaiza
  3. Randy A Planegger
  4. Matthew D Weitzman
  5. John V Moran
(2014)
APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition
eLife 3:e02008.
https://doi.org/10.7554/eLife.02008

Share this article

https://doi.org/10.7554/eLife.02008

Further reading

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Daniel Hui, Scott Dudek ... Marylyn D Ritchie
    Research Article

    Apart from ancestry, personal or environmental covariates may contribute to differences in polygenic score (PGS) performance. We analyzed the effects of covariate stratification and interaction on body mass index (BMI) PGS (PGSBMI) across four cohorts of European (N = 491,111) and African (N = 21,612) ancestry. Stratifying on binary covariates and quintiles for continuous covariates, 18/62 covariates had significant and replicable R2 differences among strata. Covariates with the largest differences included age, sex, blood lipids, physical activity, and alcohol consumption, with R2 being nearly double between best- and worst-performing quintiles for certain covariates. Twenty-eight covariates had significant PGSBMI–covariate interaction effects, modifying PGSBMI effects by nearly 20% per standard deviation change. We observed overlap between covariates that had significant R2 differences among strata and interaction effects – across all covariates, their main effects on BMI were correlated with their maximum R2 differences and interaction effects (0.56 and 0.58, respectively), suggesting high-PGSBMI individuals have highest R2 and increase in PGS effect. Using quantile regression, we show the effect of PGSBMI increases as BMI itself increases, and that these differences in effects are directly related to differences in R2 when stratifying by different covariates. Given significant and replicable evidence for context-specific PGSBMI performance and effects, we investigated ways to increase model performance taking into account nonlinear effects. Machine learning models (neural networks) increased relative model R2 (mean 23%) across datasets. Finally, creating PGSBMI directly from GxAge genome-wide association studies effects increased relative R2 by 7.8%. These results demonstrate that certain covariates, especially those most associated with BMI, significantly affect both PGSBMI performance and effects across diverse cohorts and ancestries, and we provide avenues to improve model performance that consider these effects.

    1. Genetics and Genomics
    Sedigheh Delmaghani, Aziz El-Amraoui
    Insight

    The DYRK1A enzyme is a pivotal contributor to frequent and severe episodes of otitis media in Down syndrome, positioning it as a promising target for therapeutic interventions.